ArticleThe Journal of clinical endocrinology and metabolism2011

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

David S Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.